Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
Stock Information for Lyra Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.